Skip to content
10-K

Annual Report

Ernexa Therapeutics Inc. ERNA ERNAW

0001493152-25-010051

← back to feed
Filed
Mar 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 10, 2025 52.24M sh
Cash And Equivalents FY 2024 · Dec 31, 2024 $1.73M
Cash And Equivalents FY 2024 · Dec 31, 2023 $7.58M
Shares Diluted FY 2024 · Dec 31, 2023 5.31M sh
Capex FY 2024 · Dec 31, 2023 $19K
Operating Cash Flow FY 2024 · Dec 31, 2023 −$20.41M
Current Liabilities FY 2024 · Dec 31, 2023 $6.57M
Total Liabilities FY 2024 · Dec 31, 2023 $46.9M
Current Assets FY 2024 · Dec 31, 2023 $9.6M
Total Assets FY 2024 · Dec 31, 2023 $49.13M
Eps Diluted FY 2024 · Dec 31, 2023 −$4.08
Eps Basic FY 2024 · Dec 31, 2023 −$4.08
Net Income FY 2024 · Dec 31, 2023 −$21.67M
Operating Income FY 2024 · Dec 31, 2023 −$21.14M
Gross Profit FY 2024 · Dec 31, 2023 −$168K
Cost Of Revenue FY 2024 · Dec 31, 2023 $236K
Stockholders Equity FY 2024 · Dec 31, 2022 $12.11M